Skip to main content
Top
Published in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019

01-10-2019 | Original Article

Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck

Authors: Amit Bahl, Naresh Kumar Panda, Arun Elangovan, Jaimanti Bakshi, Roshan Verma, Satyawati Mohindra, Rijuneeta Gupta, Arun Singh Oinam, Satinder Kaur, R. K. Vashishta, Sushmita Ghoshal

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery | Special Issue 1/2019

Login to get access

Abstract

Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05).
Literature
1.
go back to reference Gomez DR, Hoppe BS, Wolden SL et al (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70:1365–1372CrossRef Gomez DR, Hoppe BS, Wolden SL et al (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70:1365–1372CrossRef
2.
go back to reference Coco- Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of head and neck- an update. Oral Oncol 51:652–661CrossRef Coco- Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of head and neck- an update. Oral Oncol 51:652–661CrossRef
3.
go back to reference Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159CrossRef Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159CrossRef
4.
go back to reference Cordesmeyer R, Schliephake H, Kauffmann P et al (2017) Clinical prognostic factors of salivary adenoid cystic carcinoma: a single-center analysis of 61 patients. J Craniomaxillofac Surg 45:1784–1787CrossRef Cordesmeyer R, Schliephake H, Kauffmann P et al (2017) Clinical prognostic factors of salivary adenoid cystic carcinoma: a single-center analysis of 61 patients. J Craniomaxillofac Surg 45:1784–1787CrossRef
5.
go back to reference Ali S, Palmer FL, Katabi N et al (2017) Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 127:2265–2269CrossRef Ali S, Palmer FL, Katabi N et al (2017) Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 127:2265–2269CrossRef
6.
go back to reference Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951CrossRef Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951CrossRef
7.
go back to reference Kim Y, Lee SJ, Lee JY et al (2017) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 123:1958–1964CrossRef Kim Y, Lee SJ, Lee JY et al (2017) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 123:1958–1964CrossRef
8.
go back to reference Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head andneck: a review. Head Neck 33:905–911CrossRef Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head andneck: a review. Head Neck 33:905–911CrossRef
9.
go back to reference Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary gland expressing c-kit: a Princess Margret Hospital phase II consortium study. J Clin Oncol 23:585–590CrossRef Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary gland expressing c-kit: a Princess Margret Hospital phase II consortium study. J Clin Oncol 23:585–590CrossRef
10.
go back to reference Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 33:25–31CrossRef Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 33:25–31CrossRef
11.
go back to reference Silverman DA, Carlson TP, Khuntia D et al (2004) Role of postoperative radiotherapy in adenoid cystic carcinoma of head and neck. Laryngoscope 114:1194–1199CrossRef Silverman DA, Carlson TP, Khuntia D et al (2004) Role of postoperative radiotherapy in adenoid cystic carcinoma of head and neck. Laryngoscope 114:1194–1199CrossRef
12.
go back to reference Takebayashi S, Shinohara S, Tamaki H et al (2018) Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol 38:73–79CrossRef Takebayashi S, Shinohara S, Tamaki H et al (2018) Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol 38:73–79CrossRef
13.
go back to reference Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149–152CrossRef Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149–152CrossRef
14.
go back to reference Dillon PM, Chakraborty S, Moskaluk CA et al (2016) Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 38:620–627CrossRef Dillon PM, Chakraborty S, Moskaluk CA et al (2016) Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 38:620–627CrossRef
15.
go back to reference Mino M, Pilch BZ, Faquin MD (2003) Expression of KIT (CD117) in neoplasm of the head and neck:an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16:1224–1231CrossRef Mino M, Pilch BZ, Faquin MD (2003) Expression of KIT (CD117) in neoplasm of the head and neck:an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16:1224–1231CrossRef
16.
go back to reference Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin Cancer Res 9:1248–1252PubMed Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin Cancer Res 9:1248–1252PubMed
17.
go back to reference Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRef Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRef
18.
go back to reference Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273CrossRef Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273CrossRef
Metadata
Title
Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck
Authors
Amit Bahl
Naresh Kumar Panda
Arun Elangovan
Jaimanti Bakshi
Roshan Verma
Satyawati Mohindra
Rijuneeta Gupta
Arun Singh Oinam
Satinder Kaur
R. K. Vashishta
Sushmita Ghoshal
Publication date
01-10-2019
Publisher
Springer India
Published in
Indian Journal of Otolaryngology and Head & Neck Surgery / Issue Special Issue 1/2019
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-018-1442-0

Other articles of this Special Issue 1/2019

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019 Go to the issue